FdaApplication
NDA 205596
Identifiers
- fda_app_no: NDA205596
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK SHARP AND DOHME CORP |
| application_type | NDA |
| approval_date | 2014-03-13 |
Revenue by product
NOXAFIL
| Period | Revenue |
|---|---|
| Q4 2024 | $36.0M |
| Q3 2024 | $41.0M |
| Q2 2024 | $45.0M |
| Q1 2024 | $56.0M |
| Q4 2023 | $46.0M |
| Q3 2023 | $51.0M |
| Q2 2023 | $55.0M |
| Q1 2023 | $60.0M |
| Q4 2022 | $58.0M |
| Q3 2022 | $62.0M |
| Q2 2022 | $60.0M |
| Q1 2022 | $57.0M |
| Q4 2021 | $62.0M |
| Q3 2021 | $64.0M |
| Q2 2021 | $66.0M |
| Q1 2021 | $67.0M |
| Q4 2020 | $82.0M |
| Q3 2020 | $79.0M |
| Q2 2020 | $73.0M |
| Q1 2020 | $94.0M |
| Q4 2019 | $102.0M |
| Q3 2019 | $177.0M |
| Q2 2019 | $193.0M |
| Q1 2019 | $190.0M |
| Q4 2018 | $191.0M |
| Q3 2018 | $188.0M |
| Q2 2018 | $188.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NOXAFIL | POSACONAZOLE | 300MG/16.7ML (18MG/ML) | SOLUTION;INTRAVENOUS |
1 product